NEW

Genixus Introduces New Propofol RTA Syringe

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, will offer Propofol as the first product within its KinetiX platform of RTA syringe products at the Annual National Pharmacy Purchasing Association Conference (Booth...

Cohen Children’s Medical Center Unveils $110M Pediatric Surgical Operating Complex

Cohen Children’s Medical Center has announced the opening of the Pediatric Surgical Operating Complex, a $110 million, 24,000-square-foot, state-of-the-art home for pediatric surgery that greatly enhances the capabilities of New York State’s No. 1 provider of...

AAAHC Calls for 2022-23 Bernard A. Kershner Innovations in Quality Improvement Award Submissions

Today, the Accreditation Association for Ambulatory Health Care (AAAHC) opens submissions for the 2022-23 Bernard A. Kershner Innovations in Quality Improvement (QI) Awards. Named in honor of the late Bernard A. Kershner, a leader in ambulatory health care and...

Movano Ring Company Eyes FDA Submission

Movano Inc., a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, announces today the successful completion of a study with the University of California San Francisco (UCSF) to assess the accuracy of the Movano Ring’s...

Exero Medical’s Smart Sensor Granted FDA Breakthrough Designation

Exero MedicalExero Medical, developer of a wireless system for early detection of anastomotic leaks (AL) following gastrointestinal (GI) surgery, today announced that it has been granted FDA Breakthrough Designation – a status reserved for medical devices that provide more effective treatment or diagnosis of potentially life-threatening or irreversible conditions or diseases.

To achieve this status, Exero Medical demonstrated that its smart sensor for the early detection of potentially lethal AL following GI surgery, represents a breakthrough that may demonstrate substantial improvement over any available solution.

“In the realm of early detection of AL, there is currently no technology that offers clinicians insights on the state of a patient’s internal tissue healing following resection surgery in the GI,” explained Erez Shor, PhD., CEO of Exero Medical. “The time needed today to obtain definitive diagnosis of a leak often puts the patient in a critical state of health. Alternatively, some surgeons order invasive interventions as a precautionary step, putting patients through often-unnecessary additional procedures. Our system is designed to provide clinicians the needed data on tissue healing well before a patient reaches a catastrophic situation, enabling more precise and effective intervention, minimizing complications and potentially saving lives.”

To confirm that Exero’s smart sensor may provide effective early diagnosis of AL, the FDA scrutinized the company’s pre-clinical data from its animal studies as well as clinical data collected in the first in-human feasibility trial conducted at Rabin Medical Center.

“We are thrilled to work with the FDA to optimize our regulatory process. I expect the rapid interaction with FDA will reduce our time to market,” added Shor.”

“Erez and his team have developed a life-saving technology using a multi-disciplinary approach to medical device development that will have a significant impact on the GI surgical market,” said Shai Policker, CEO of MEDX Xelerator. “Achieving the FDA’s Breakthrough Designation at this stage attests to the quality of their initial R&D and the urgent need for this technology to reach the hands of clinicians.”

Exero Medical is a portfolio company of MEDX Xelerator, a medical device and digital health focused incubator based in Israel, formed as a partnership between Boston Scientific, MEDX Ventures and Sheba Medical Center.

Previous

Next

Submit a Comment

Your email address will not be published.

X